Lawrence A. Kenyon Buys 5,000 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CFO Lawrence A. Kenyon bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were purchased at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the acquisition, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Outlook Therapeutics Stock Performance

Shares of Outlook Therapeutics stock opened at $5.22 on Wednesday. Outlook Therapeutics, Inc. has a 52-week low of $4.34 and a 52-week high of $18.00. The stock has a market capitalization of $122.18 million, a price-to-earnings ratio of -0.46 and a beta of 0.64. The company has a fifty day moving average of $7.11 and a 200-day moving average of $7.75.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.23. On average, equities research analysts forecast that Outlook Therapeutics, Inc. will post -3.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OTLK has been the topic of a number of analyst reports. Ascendiant Capital Markets decreased their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Chardan Capital reissued a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a report on Friday, August 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday, August 15th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Outlook Therapeutics has an average rating of “Buy” and a consensus price target of $48.20.

Institutional Investors Weigh In On Outlook Therapeutics

A number of institutional investors have recently made changes to their positions in OTLK. AQR Capital Management LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at $75,000. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at $232,000. Susquehanna Fundamental Investments LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at $303,000. LVW Advisors LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at $352,000. Finally, Rosalind Advisors Inc. boosted its position in Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after buying an additional 138,225 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.